Table 2 Demographic and clinical features according to rifaximin response
From: Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome
Responders N (%) | Non-responders N (%) | P value | |
|---|---|---|---|
N (%) | 8 (42.1) | 11 (57.9) | 0.74 |
Male | 2 (25) | 5 (75) | 0.37 |
Age, years (SD) | 57.6 (19.5) | 55.6 (17.1) | 0.72 |
Medications | |||
Anticholinergics | 1 (12.5) | 4 (36.4) | 0.31 |
Calcium channel blocker | 1 (12.5) | 2 (18.2) | 1.00 |
Proton pump inhibitor | 5 (62.5) | 7 (63.6) | 1.00 |
Comorbidities | |||
Diabetes mellitus | 3 (37.5) | 2 (18.2) | 0.61 |
Scleroderma | 0 (0) | 0 (0) | 1.00 |
Sjogren’s syndrome | 1 (12.5) | 1 (9.1) | 1.00 |